Latest Raloxifene Stories
INDIANAPOLIS, Sept. 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S.
Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use.
MUNICH, June 28, 2010 /PRNewswire/ -- - 3D Images Provide New Approach to Monitoring Bone Changes Interim data from a prospective Investigator Initiated Trial (IIT) presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA(R) (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the treatment and prevention of osteoporosis in postmenopausal women, improves bone quality as measured by the...
Women taking tamoxifen for early-stage breast cancer who developed blood clots were more likely to carry a gene mutation for clotting than women taking tamoxifen who did not develop blood clots.
MORRISTOWN, N.J., May 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S.
An estrogenic drug that influences neurotransmitter and neuronal systems inthe brain is showing promise as an effective therapy for women who suffer from schizophrenia.
Women with breast cancer who take the antidepressant paroxetine at the same time as tamoxifen are at an increased risk of death.
Endocrinologists at the University of Pittsburgh School of Medicine and UPMC are launching a human trial of a new drug that their research indicates holds great promise for building bones weakened by osteoporosis.
INDIANAPOLIS, Sept. 23 /PRNewswire-FirstCall/ -- The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's (NYSE: LLY) method-of-use patents on Evista(R) (raloxifene HCl tablets). In the case of Eli Lilly and Company v.
Although tamoxifen, raloxifen and tibolone dramatically reduce the risk of invasive breast cancer, some patients experience adverse effects.
- Of or relating to good digestion.